You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Rezvoglar ™ (insulin glargine-aglr) injection
3 mL (100 units/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Rezvoglar™ (insulin glargine-aglr) a biosimilar to Lantus® (insulin glargine)?
Rezvoglar is biosimilar to Lantus.
Biosimilarity of Rezvoglar to Lantus
Rezvoglar™ (insulin glargine-aglr) 100 units/mL is biosimilar to Lantus® (insulin glargine).1
Definition of a Biosimilar Product
Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of Rezvoglar has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.1
Enclosed Prescribing Information
References
1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: November 24, 2025